Moxalactam therapy for neonatal meningitis due to gram-negative enteric bacilli. A prospective controlled evaluation.
Moxalactam and ampicillin sodium therapy were compared with amikacin sulfate and ampicillin therapy for meningitis due to gram-negative enteric bacilli in 63 infants enrolled in the Third Neonatal Meningitis Cooperative Study. The population characteristics and causative organisms were comparable for the two treatment groups. Cultures of CSF were positive for approximately three days in both study groups. Case-fatality rates were 23% and 15% for moxalactam-treated infants and ampicillin- and amikacin-treated infants, respectively. Developmental or neurological abnormalities were found in about 40% of survivors, and the rates were comparable for both treatment groups. Computed tomograms in 44 infants were interpreted as normal in 13 (30%); hydrocephalus, abscesses, and low-density areas were the most frequent abnormalities. We conclude that moxalactam is a suitable alternative for treatment of meningitis due to gram-negative enteric bacilli.
D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use; D000667:Ampicillin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004756:Enterobacteriaceae Infections / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D006090:Gram-Negative Bacteria; D006801:Humans; D007231:Infant, Newborn; D008581:Meningitis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D009070:Moxalactam / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011859:Radiography
D000667:Ampicillin; D000583:Amikacin; D009070:Moxalactam